What is SI-BONE, Inc.'s earnings per share (EPS)?

SI-BONE, Inc. (SIBN) reported diluted earnings per share of -$0.44 for fiscal year 2025. This represents a 41.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

SI-BONE, Inc. (SIBN) Financials

SIBN

Trailing 12 months to June 30, 2026

Revenue $213.6M +15.3% YoY

Net Income -$14.6M +38.4% YoY

EPS (Diluted) -$0.34 +39.3% YoY

Free Cash Flow -$4.4M +65.5% YoY

Market Cap $868.1M as of Oct 10, 2026

Price / Sales 4.1x on $213.6M revenue, trailing 12 months to June 30, 2026

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to June 30, 2026

Price / Book 4.8x on $182.3M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 4, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 4, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the SIBN SEC filings page.

SI-BONE, Inc. (SIBN) reported $213.6M in revenue over the twelve months to Jun 30, 2026, up 15.3% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI SIBN FY2025 2026-10-03

Revenue growth is increasingly covering operating costs, but the business still needs capital investment to reach positive free cash flow.

Operating cash flow improved from -$12.4M in FY2024 to nearly break-even at -$675K in FY2025, yet free cash flow remained negative at -$9.1M because capital expenditures consumed $8.4M. The narrowing gap therefore reflects improving day-to-day economics while reinvestment still absorbs cash.

Gross margin fell from 88.4% in FY2021 to 79.6% in FY2025, so the improvement was not driven by richer unit economics. Meanwhile, operating margin improved from -57.3% to -11.1%, indicating that revenue growth and expense absorption outweighed the margin compression.

The balance sheet is lightly levered: debt-to-equity was 0.2x and the current ratio was 8.5x in FY2025, allowing losses to be financed without heavy borrowing. Inventory rose 25.1% during FY2025, faster than revenue, making working capital a larger operational commitment even as cash losses shrank.

Financial Health Signals

Financial Health Score 53/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of SI-BONE, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

SI-BONE, Inc. has an operating margin of -11.1%, meaning the company loses $11 on every $100 of revenue. This results in a profitability score of 24/100. This is up from -21.1% the prior year.

Growth

SI-BONE, Inc.'s revenue surged 20.2% year-over-year to $200.9M, reflecting rapid business expansion. This strong growth earns a score of 82/100.

Leverage

SI-BONE, Inc. carries a low D/E ratio of 0.20, meaning only $0.20 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 75/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 8.55, SI-BONE, Inc. holds $8.55 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 97/100.

Cash Flow

SI-BONE, Inc.'s operations used $675K of cash, and capex of $8.4M added to the outflow, for a free cash flow shortfall of $9.1M. This results in a cash flow score of 12/100.

Returns

SI-BONE, Inc. posts a -10.7% return on equity (ROE), meaning it loses $11 for every $100 of shareholders' equity. This results in a returns score of 27/100. This is up from -18.5% the prior year.

Altman Z-Score Safe

7.39

SI-BONE, Inc. scores 7.39, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($868.1M) relative to total liabilities ($61.0M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Neutral

6/9

SI-BONE, Inc. passes 6 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality No Cash Backing

N/A

SI-BONE, Inc. reported a net loss of $18.9M while operations used $675K of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

SI-BONE, Inc. reported an operating loss of $22.3M against $2.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$56.0M

YoY+15.2%

QoQ+6.5%

5Y CAGR+20.3%

SI-BONE, Inc. generated $56.0M in revenue in Q2 2026. This represents an increase of 15.2% from the same quarter a year earlier. Against the prior quarter it is up 6.5%.

EBITDA

-$3.1M

YoY+44.6%

QoQ+10.6%

SI-BONE, Inc.'s EBITDA was -$3.1M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 44.6% from the same quarter a year earlier. Against the prior quarter it is up 10.6%.

Net Income

-$4.1M

YoY+33.6%

QoQ+5.7%

SI-BONE, Inc. reported -$4.1M in net income in Q2 2026. This represents an increase of 33.6% from the same quarter a year earlier. Against the prior quarter it is up 5.7%.

EPS (Diluted)

-$0.09

YoY+35.7%

QoQ+10.0%

SI-BONE, Inc. earned -$0.09 per diluted share (EPS) in Q2 2026. This represents an increase of 35.7% from the same quarter a year earlier. Against the prior quarter it is up 10.0%.

Cash & Balance Sheet

Free Cash Flow

-$768K

YoY+60.1%

QoQ+77.7%

SI-BONE, Inc. recorded an outflow of $768K in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 60.1% from the same quarter a year earlier. Against the prior quarter it is up 77.7%.

Cash & Debt

$33.1M

YoY-3.0%

QoQ-1.2%

5Y CAGR-7.2%

SI-BONE, Inc. held $33.1M in cash against $35.6M in long-term debt as of Q2 2026.

Shares Outstanding

45M

YoY+3.9%

QoQ+1.1%

5Y CAGR+6.1%

SI-BONE, Inc. had 45M shares outstanding in Q2 2026. This represents an increase of 3.9% from the same quarter a year earlier. Against the prior quarter it is up 1.1%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

79.5%

YoY-0.3pp

QoQ-0.2pp

5Y change-9.8pp

SI-BONE, Inc.'s gross margin was 79.5% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 0.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.2 percentage points.

Operating Margin

-8.6%

YoY+5.8pp

QoQ+1.1pp

5Y change+49.8pp

SI-BONE, Inc.'s operating margin was -8.6% in Q2 2026, reflecting core business profitability. This is up 5.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.1 percentage points.

Net Margin

-7.3%

YoY+5.4pp

QoQ+0.9pp

5Y change+55.7pp

SI-BONE, Inc.'s net profit margin was -7.3% in Q2 2026, showing the share of revenue converted to profit. This is up 5.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.9 percentage points.

Return on Equity

-2.2%

YoY+1.4pp

QoQ+0.2pp

5Y change+6.8pp

SI-BONE, Inc.'s ROE was -2.2% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 1.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.2 percentage points.

Capital Allocation

R&D Spending

$5.2M

YoY+21.2%

QoQ+24.5%

5Y CAGR+10.6%

SI-BONE, Inc. invested $5.2M in research and development in Q2 2026. This represents an increase of 21.2% from the same quarter a year earlier. Against the prior quarter it is up 24.5%.

Capital Expenditures

$1.5M

YoY-26.4%

QoQ+43.5%

5Y CAGR-7.0%

SI-BONE, Inc. invested $1.5M in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 26.4% from the same quarter a year earlier. Against the prior quarter it is up 43.5%.

Share Buybacks

Not reported for Q2 2026.

SIBN Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SIBN quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K
Revenue	$213.6M	$200.9M+20.2%	$167.2M+20.4%	$138.9M+30.5%	$106.4M+18.0%	$90.2M+22.8%	$73.4M+9.0%	$67.3M+21.5%	$55.4M+15.4%	$48.0M
Cost of Revenue	$43.7M	$41.0M+17.1%	$35.1M+19.0%	$29.5M+87.6%	$15.7M+50.6%	$10.4M+17.1%	$8.9M+31.1%	$6.8M+40.5%	$4.8M-5.5%	$5.1M
Gross Profit	$169.9M	$159.9M+21.0%	$132.1M+20.7%	$109.4M+20.6%	$90.7M+13.8%	$79.7M+23.6%	$64.5M+6.6%	$60.5M+19.7%	$50.5M+17.9%	$42.9M
R&D Expenses	$18.0M	$17.4M+5.4%	$16.6M+10.2%	$15.0M+10.3%	$13.6M+9.5%	$12.4M+31.5%	$9.5M+29.9%	$7.3M+35.4%	$5.4M-2.5%	$5.5M
SG&A Expenses	$40.0M	$40.5M+20.1%	$33.8M+8.6%	$31.1M+7.3%	$29.0M+15.5%	$25.1M+26.6%	$19.8M-5.6%	$21.0M+66.0%	$12.6M-3.2%	$13.1M
Operating Income	-$17.7M	-$22.3M+36.6%	-$35.2M+24.9%	-$46.9M+21.3%	-$59.6M-15.4%	-$51.7M-34.0%	-$38.6M-7.1%	-$36.0M-200.9%	-$12.0M+31.0%	-$17.4M
EBITDA	N/A	-$16.6M+46.4%	-$30.9M+25.6%	-$41.5M+26.1%	-$56.2M-13.3%	-$49.6M-32.4%	-$37.4M-6.3%	-$35.2M-213.3%	-$11.2M+31.2%	-$16.3M
Interest Expense	$2.5M	$2.6M-23.6%	$3.4M-0.6%	$3.5M+22.8%	$2.8M-47.5%	$5.4M-12.1%	$6.1M+23.3%	$4.9M-3.1%	$5.1M-17.7%	$6.2M
Income Tax	$0	$0	$0	$0	$0	$0	N/A	N/A	$0	$0
Net Income	-$14.6M	-$18.9M+38.8%	-$30.9M+28.6%	-$43.3M+29.4%	-$61.3M-8.3%	-$56.6M-29.5%	-$43.7M-13.8%	-$38.4M-120.0%	-$17.5M+24.2%	-$23.0M
EPS (Basic)	N/A	-$0.44+41.3%	-$0.75+33.6%	-$1.13+36.9%	-$1.79-4.7%	-$1.71-14.0%	-$1.50	N/A	N/A	N/A
EPS (Diluted)	-$0.34	-$0.44+41.3%	-$0.75+33.6%	-$1.13+36.9%	-$1.79-4.7%	-$1.71-14.0%	-$1.50	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	43M+3.6%	41M+7.9%	38M+12.4%	34M+3.2%	33M+14.1%	29M	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$56.0M+15.2%	$52.6M+11.2%	$56.3M+15.0%	$48.7M+20.6%	$48.6M+21.7%	$47.3M+24.9%	$49.0M+26.1%	$40.3M+18.6%
Cost of Revenue	$11.5M+16.7%	$10.6M+10.9%	$11.8M+15.6%	$9.8M+16.3%	$9.8M+17.0%	$9.6M+19.9%	$10.2M+0.4%	$8.4M+19.8%
Gross Profit	$44.5M+14.8%	$41.9M+11.3%	$44.5M+14.8%	$38.8M+21.8%	$38.8M+22.9%	$37.7M+26.2%	$38.8M+35.2%	$31.9M+18.3%
R&D Expenses	$5.2M+21.2%	$4.2M-7.5%	$4.4M+12.7%	$4.2M+6.2%	$4.3M-1.0%	$4.5M+4.3%	$3.9M-7.0%	$4.0M+1.9%
SG&A Expenses	$10.1M-5.7%	$10.0M+0.8%	$9.8M+7.4%	$10.0M+23.9%	$10.7M+28.7%	$10.0M+21.8%	$9.2M+13.2%	$8.1M+5.0%
Operating Income	-$4.8M+31.4%	-$5.1M+31.9%	-$2.5M+55.2%	-$5.4M+29.5%	-$7.0M+30.5%	-$7.5M+37.9%	-$5.5M+56.1%	-$7.6M+31.7%
EBITDA	-$3.1M+44.6%	-$3.5M+44.0%	-$871K+79.8%	-$3.9M+40.6%	-$5.6M+38.3%	-$6.2M+43.4%	-$4.3M+60.4%	-$6.5M+32.4%
Interest Expense	$598K-10.2%	$592K-10.6%	$630K-20.8%	$670K-24.2%	$666K-24.3%	$662K-24.9%	$795K-10.7%	$884K0.0%
Income Tax	$0	$0	$0	$0	$0	$0	$0	$0
Net Income	-$4.1M+33.6%	-$4.3M+33.8%	-$1.6M+63.4%	-$4.6M+30.6%	-$6.2M+31.2%	-$6.5M+40.0%	-$4.5M+59.1%	-$6.6M+34.4%
EPS (Basic)	-$0.09+35.7%	-$0.10+33.3%	-$0.04+63.6%	-$0.11+31.3%	-$0.14+36.4%	-$0.15+44.4%	-$0.11+59.3%	-$0.16+36.0%
EPS (Diluted)	-$0.09+35.7%	-$0.10+33.3%	-$0.04+63.6%	-$0.11+31.3%	-$0.14+36.4%	-$0.15+44.4%	-$0.11+59.3%	-$0.16+36.0%
Diluted Shares (Avg)	44M+3.9%	44M+3.8%	N/A	43M+3.5%	43M+3.6%	42M+3.4%	N/A	42M+3.6%

SIBN Balance Sheet

SIBN quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K
Total Assets	$238.6M+3.5%	$230.4M0.0%	$230.4M+46.3%	$157.6M-17.3%	$190.5M-14.6%	$223.1M+90.7%	$117.0M-15.5%	$138.5M+286.6%	$35.8M
Current Assets	$216.1M+4.0%	$207.8M-1.7%	$211.4M+53.6%	$137.6M-21.8%	$175.9M-19.4%	$218.2M+95.8%	$111.5M-18.1%	$136.0M+304.5%	$33.6M
Cash & Equivalents	$42.2M+20.9%	$34.9M+5.0%	$33.3M+60.6%	$20.7M-67.3%	$63.4M+18.4%	$53.6M+413.5%	$10.4M-58.5%	$25.1M+12.1%	$22.4M
Short-Term Investments	$105.6M-8.3%	$115.1M-13.3%	$132.7M+73.4%	$76.6M-8.4%	$83.6M-41.5%	$142.9M+75.6%	$81.3M-16.2%	$97.1M	$0
Inventory	$33.9M+25.2%	$27.1M+33.7%	$20.2M+17.2%	$17.3M+50.3%	$11.5M+104.1%	$5.6M+3.3%	$5.5M+63.1%	$3.3M+30.9%	$2.6M
Accounts Receivable	$29.9M+8.9%	$27.5M+25.1%	$22.0M+6.2%	$20.7M+45.1%	$14.2M+4.7%	$13.6M+16.1%	$11.7M+38.1%	$8.5M+14.4%	$7.4M
Long-Term Investments	$0	$0	$0	$0	$0	$0-100.0%	$1.3M	$0	$0
Total Liabilities	$61.0M-3.9%	$63.5M+4.0%	$61.0M+3.0%	$59.3M+5.6%	$56.1M+4.3%	$53.8M-0.4%	$54.0M+11.7%	$48.3M-70.7%	$165.2M
Current Liabilities	$25.3M-6.8%	$27.1M+15.7%	$23.5M+10.8%	$21.2M+25.4%	$16.9M+25.4%	$13.5M-28.3%	$18.8M+108.5%	$9.0M+19.5%	$7.5M
Non-Current Liabilities	$35.7M-1.6%	$36.3M-3.3%	$37.6M-1.3%	$38.1M-2.9%	$39.2M-2.8%	$40.3M+14.4%	$35.2M-10.4%	$39.3M-75.1%	$157.7M
Long-Term Debt	$35.6M+0.3%	$35.5M-1.7%	$36.1M+2.5%	$35.2M+0.6%	$35.0M-11.4%	$39.5M+13.2%	$34.9M-10.5%	$39.0M+0.7%	$38.7M
Total Equity	$177.5M+6.3%	$167.0M-1.4%	$169.4M+72.3%	$98.3M-26.9%	$134.4M-20.6%	$169.4M+168.8%	$63.0M-30.1%	$90.2M+169.7%	-$129.4M
Retained Earnings	-$450.3M-4.4%	-$431.4M-7.7%	-$400.4M-12.1%	-$357.1M-20.7%	-$295.8M-23.6%	-$239.3M-22.3%	-$195.6M-24.4%	-$157.2M-12.5%	-$139.7M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$248.8M+7.7%	$242.7M+6.8%	$238.6M+3.5%	$234.3M+3.2%	$230.9M+3.2%	$227.3M+1.6%	$230.4M0.0%	$227.0M-1.7%
Current Assets	$219.9M+6.0%	$214.7M+5.2%	$216.1M+4.0%	$210.8M+3.5%	$207.4M+2.5%	$204.2M+0.3%	$207.8M-1.7%	$203.7M-3.5%
Cash & Equivalents	$33.1M-3.0%	$33.5M-18.6%	$42.2M+20.9%	$26.5M-12.4%	$34.1M+33.5%	$41.2M+28.5%	$34.9M+5.0%	$30.2M-43.5%
Short-Term Investments	$112.8M+1.3%	$111.1M+7.7%	$105.6M-8.3%	$119.3M-1.1%	$111.4M-11.6%	$103.2M-17.9%	$115.1M-13.3%	$120.6M+6.5%
Inventory	$38.4M+12.1%	$35.5M+17.0%	$33.9M+25.2%	$35.7M+40.0%	$34.2M+47.4%	$30.4M+44.3%	$27.1M+33.7%	$25.5M+14.3%
Accounts Receivable	$31.2M+27.9%	$31.0M+15.9%	$29.9M+8.9%	$26.5M+6.5%	$24.4M-1.7%	$26.7M+20.8%	$27.5M+25.1%	$24.9M+24.6%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$66.4M+9.6%	$63.8M+6.3%	$61.0M-3.9%	$62.1M+0.2%	$60.6M+2.5%	$60.0M+3.2%	$63.5M+4.0%	$62.0M+8.3%
Current Liabilities	$24.0M-2.9%	$21.5M-10.3%	$25.3M-6.8%	$26.4M+7.1%	$24.8M+12.2%	$24.0M+14.8%	$27.1M+15.7%	$24.7M+27.4%
Non-Current Liabilities	$42.4M+18.3%	$42.3M+17.3%	$35.7M-1.6%	$35.7M-4.4%	$35.8M-3.3%	$36.1M-3.4%	$36.3M-3.3%	$37.3M-1.5%
Long-Term Debt	$35.6M+0.3%	$35.6M+0.3%	$35.6M+0.3%	$35.5M-1.8%	$35.5M-1.8%	$35.5M-1.7%	$35.5M-1.7%	$36.2M+0.5%
Total Equity	$182.3M+7.0%	$178.9M+7.0%	$177.5M+6.3%	$172.1M+4.3%	$170.3M+3.4%	$167.3M+1.0%	$167.0M-1.4%	$165.0M-5.0%
Retained Earnings	-$458.7M-3.3%	-$454.6M-3.8%	-$450.3M-4.4%	-$448.6M-5.1%	-$444.0M-5.7%	-$437.9M-6.5%	-$431.4M-7.7%	-$426.9M-9.6%

Not reported in any period shown, so not listed: Goodwill.

SIBN Cash Flow Statement

SIBN quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K
Operating Cash Flow	$2.5M	-$675K+94.6%	-$12.4M+33.6%	-$18.7M+55.1%	-$41.7M-5.4%	-$39.5M-28.9%	-$30.7M+3.1%	-$31.6M-117.8%	-$14.5M+17.2%	-$17.5M
Depreciation & Amortization	N/A	$5.8M+31.8%	$4.4M-19.3%	$5.4M+57.2%	$3.5M+65.5%	$2.1M+84.6%	$1.1M+46.0%	$774K+7.2%	$722K-28.7%	$1.0M
Stock-Based Compensation	N/A	$25.5M-1.3%	$25.9M+7.5%	$24.1M+4.3%	$23.1M+36.7%	$16.9M+41.4%	$11.9M+59.8%	$7.5M+222.8%	$2.3M+60.8%	$1.4M
Capital Expenditures	$6.9M	$8.4M-19.8%	$10.5M+34.6%	$7.8M-18.0%	$9.5M+48.8%	$6.4M+149.5%	$2.6M+4.7%	$2.4M+159.6%	$942K+97.1%	$478K
Free Cash Flow	-$4.4M	-$9.1M+60.3%	-$22.9M+13.5%	-$26.5M+48.2%	-$51.2M-11.4%	-$45.9M-38.2%	-$33.2M+2.5%	-$34.1M-120.4%	-$15.5M+14.1%	-$18.0M
Investing Cash Flow	-$6.0M	$4.2M-67.0%	$12.6M+121.1%	-$59.8M-2024.3%	-$2.8M-105.5%	$51.6M+182.0%	-$62.9M-566.4%	$13.5M+113.8%	-$97.8M-20365.5%	-$478K
Financing Cash Flow	$2.7M	$3.4M+72.4%	$2.0M-97.8%	$90.9M+4039.0%	$2.2M+228.4%	-$1.7M-101.3%	$136.4M+3810.6%	$3.5M-97.0%	$115.2M+795.3%	$12.9M
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$38K-47.9%	$73K	$0

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	$777K+349.1%	-$2.4M+51.9%	$1.7M+46.7%	$2.3M+673.2%	$173K+102.7%	-$4.9M+35.1%	$1.2M+151.3%	$302K+114.6%
Depreciation & Amortization	$1.7M+21.4%	$1.6M+26.5%	$1.6M+35.0%	$1.5M+36.4%	$1.4M+40.0%	$1.3M+17.4%	$1.2M-22.9%	$1.1M-26.7%
Stock-Based Compensation	$6.0M-10.2%	$6.0M-9.6%	N/A	$6.2M-1.3%	$6.7M+4.1%	$6.7M-5.2%	N/A	$6.3M+6.4%
Capital Expenditures	$1.5M-26.4%	$1.1M-48.0%	$1.3M-43.2%	$3.0M-2.7%	$2.1M-32.6%	$2.1M-0.5%	$2.3M+107.3%	$3.0M+114.9%
Free Cash Flow	-$768K+60.1%	-$3.4M+50.8%	$440K+140.4%	-$620K+77.3%	-$1.9M+79.6%	-$7.0M+27.7%	-$1.1M+67.9%	-$2.7M+21.6%
Investing Cash Flow	-$2.7M+71.1%	-$6.2M-158.6%	$13.0M+200.3%	-$10.0M-366.0%	-$9.5M-417.5%	$10.6M+67.5%	$4.3M+122.9%	$3.8M+106.9%
Financing Cash Flow	$1.6M-27.1%	$34K-67.0%	$1.0M+1419.2%	$11K-92.9%	$2.2M+25.7%	$103K-1.9%	-$78K-109.3%	$155K+165.4%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

SIBN Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SIBN quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K
Gross Margin	79.6%+0.5pp	79.0%+0.3pp	78.8%-6.5pp	85.2%-3.2pp	88.4%+0.6pp	87.9%-2.0pp	89.9%-1.4pp	91.3%+1.9pp	89.3%
Operating Margin	-11.1%+10.0pp	-21.1%+12.7pp	-33.8%+22.2pp	-56.0%+1.3pp	-57.3%-4.8pp	-52.5%+1.0pp	-53.5%-31.9pp	-21.6%+14.5pp	-36.2%
Net Margin	-9.4%+9.1pp	-18.5%+12.7pp	-31.2%+26.4pp	-57.6%+5.2pp	-62.8%-3.2pp	-59.5%-2.5pp	-57.1%-25.6pp	-31.5%+16.5pp	-48.0%
Return on Equity	-10.7%+7.9pp	-18.5%+7.1pp	-25.6%+36.8pp	-62.4%-20.3pp	-42.1%-16.3pp	-25.8%+35.2pp	-61.0%-41.6pp	-19.4%	N/A
Return on Assets	-7.9%+5.5pp	-13.4%+5.4pp	-18.8%+20.1pp	-38.9%-9.2pp	-29.7%-10.1pp	-19.6%+13.2pp	-32.8%-20.2pp	-12.6%+51.7pp	-64.3%
Current Ratio	8.55+0.9x	7.66-1.4x	9.01+2.5x	6.50-3.9x	10.41-5.8x	16.20+10.3x	5.94-9.2x	15.11+10.6x	4.46
Debt-to-Equity	0.200.0x	0.210.0x	0.21-0.1x	0.36+0.1x	0.260.0x	0.23-0.3x	0.55+0.1x	0.43	N/A
Asset Turnover	0.84+0.1x	0.73+0.1x	0.60-0.1x	0.68+0.2x	0.47+0.1x	0.33-0.2x	0.58+0.2x	0.40-0.9x	1.34
FCF Margin	-4.5%+9.2pp	-13.7%+5.4pp	-19.1%+29.0pp	-48.1%+2.9pp	-50.9%-5.7pp	-45.3%+5.4pp	-50.6%-22.7pp	-27.9%+9.6pp	-37.5%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	79.5%-0.3pp	79.8%0.0pp	79.0%-0.1pp	79.8%+0.7pp	79.8%+0.8pp	79.7%+0.8pp	79.1%+5.3pp	79.1%-0.2pp
Operating Margin	-8.6%+5.8pp	-9.7%+6.1pp	-4.4%+6.8pp	-11.1%+7.9pp	-14.4%+10.8pp	-15.8%+16.0pp	-11.2%+21.0pp	-18.9%+13.9pp
Net Margin	-7.3%+5.4pp	-8.2%+5.6pp	-2.9%+6.2pp	-9.4%+6.9pp	-12.7%+9.7pp	-13.8%+15.0pp	-9.2%+19.0pp	-16.3%+13.2pp
Return on Equity	-2.2%+1.4pp	-2.4%+1.5pp	-0.9%+1.8pp	-2.6%+1.3pp	-3.6%+1.8pp	-3.9%+2.7pp	-2.7%+3.8pp	-4.0%+1.8pp
Return on Assets	-1.6%+1.0pp	-1.8%+1.1pp	-0.7%+1.3pp	-1.9%+1.0pp	-2.7%+1.3pp	-2.9%+2.0pp	-1.9%+2.8pp	-2.9%+1.4pp
Current Ratio	9.15+0.8x	9.99+1.5x	8.55+0.9x	7.97-0.3x	8.38-0.8x	8.53-1.2x	7.66-1.4x	8.25-2.6x
Debt-to-Equity	0.200.0x	0.200.0x	0.200.0x	0.210.0x	0.210.0x	0.210.0x	0.210.0x	0.220.0x
Asset Turnover	0.230.0x	0.220.0x	0.240.0x	0.210.0x	0.210.0x	0.210.0x	0.210.0x	0.180.0x
FCF Margin	-1.4%+2.6pp	-6.5%+8.2pp	0.8%+3.0pp	-1.3%+5.5pp	-4.0%+19.7pp	-14.8%+10.7pp	-2.2%+6.5pp	-6.8%+3.5pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
SI-BONE, Inc. SIBN	FY2025	$200.9M	-$18.9M	-9.4%	$868.1M	53/100
Tandem Diabetes Care, Inc. TNDM	FY2025	$1.0B	-$204.7M	-20.2%	$1.1B	40/100
Axogen, Inc. AXGN	FY2025	$225.2M	-$15.7M	-7.0%	$2.1B	53/100
Orthofix Medical Inc. OFIX	FY2025	$822.3M	-$92.2M	-11.2%	$373.5M	43/100
Avanos Medical, Inc. AVNS	FY2025	$701.2M	-$72.9M	-10.4%	$1.2B	44/100
ZimVie Inc. ZIMV	FY2024	$449.7M	-$25.8M	-5.7%	$535.7M	23/100

Where SI-BONE, Inc. Ranks

Frequently Asked Questions

What is SI-BONE, Inc.'s annual revenue?

SI-BONE, Inc. (SIBN) reported $200.9M in total revenue for fiscal year 2025. This represents a 20.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is SI-BONE, Inc.'s revenue growing?

SI-BONE, Inc. (SIBN) revenue grew by 20.2% year-over-year, from $167.2M to $200.9M in fiscal year 2025.

Is SI-BONE, Inc. profitable?

No, SI-BONE, Inc. (SIBN) reported a net income of -$18.9M in fiscal year 2025, with a net profit margin of -9.4%.

What is SI-BONE, Inc.'s EBITDA?

SI-BONE, Inc. (SIBN) had EBITDA of -$16.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does SI-BONE, Inc. have?

As of fiscal year 2025, SI-BONE, Inc. (SIBN) had $42.2M in cash and equivalents against $35.6M in long-term debt.

What is SI-BONE, Inc.'s gross margin?

SI-BONE, Inc. (SIBN) had a gross margin of 79.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is SI-BONE, Inc.'s operating margin?

SI-BONE, Inc. (SIBN) had an operating margin of -11.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is SI-BONE, Inc.'s net profit margin?

SI-BONE, Inc. (SIBN) had a net profit margin of -9.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is SI-BONE, Inc.'s return on equity (ROE)?

SI-BONE, Inc. (SIBN) has a return on equity of -10.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is SI-BONE, Inc.'s free cash flow?

SI-BONE, Inc. (SIBN) recorded an outflow of $9.1M in free cash flow during fiscal year 2025. This represents a 60.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is SI-BONE, Inc.'s operating cash flow?

SI-BONE, Inc. (SIBN) recorded an outflow of $675K in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are SI-BONE, Inc.'s total assets?

SI-BONE, Inc. (SIBN) had $238.6M in total assets as of fiscal year 2025, including both current and long-term assets.

What are SI-BONE, Inc.'s capital expenditures?

SI-BONE, Inc. (SIBN) invested $8.4M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does SI-BONE, Inc. spend on research and development?

SI-BONE, Inc. (SIBN) invested $17.4M in research and development during fiscal year 2025.

How many shares does SI-BONE, Inc. have outstanding?

SI-BONE, Inc. (SIBN) had 44M shares outstanding as of fiscal year 2025.

What is SI-BONE, Inc.'s current ratio?

SI-BONE, Inc. (SIBN) had a current ratio of 8.55 as of fiscal year 2025, which is generally considered healthy.

What is SI-BONE, Inc.'s debt-to-equity ratio?

SI-BONE, Inc. (SIBN) had a debt-to-equity ratio of 0.20 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is SI-BONE, Inc.'s return on assets (ROA)?

SI-BONE, Inc. (SIBN) had a return on assets of -7.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is SI-BONE, Inc.'s P/E ratio?

SI-BONE, Inc. (SIBN) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $868.1M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is SI-BONE, Inc.'s price-to-sales ratio?

SI-BONE, Inc. (SIBN) trades at 4.1x sales, its market capitalization divided by revenue of $213.6M revenue, trailing 12 months to June 30, 2026. The market capitalization is $868.1M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is SI-BONE, Inc.'s Altman Z-Score?

SI-BONE, Inc. (SIBN) has an Altman Z-Score of 7.39, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is SI-BONE, Inc.'s Piotroski F-Score?

SI-BONE, Inc. (SIBN) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are SI-BONE, Inc.'s earnings high quality?

SI-BONE, Inc. (SIBN) reported a net loss of $18.9M while operations used $675K of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can SI-BONE, Inc. cover its interest payments?

SI-BONE, Inc. (SIBN) reported an operating loss of $22.3M against $2.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is SI-BONE, Inc.?

SI-BONE, Inc. (SIBN) scores 53 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.